Royalty Pharma (RPRX) Set to Announce Earnings on Wednesday

by · The Cerbat Gem

Royalty Pharma (NASDAQ:RPRX – Get Free Report) will release its earnings data before the market opens on Wednesday, November 6th. Analysts expect Royalty Pharma to post earnings of $0.95 per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The company had revenue of $537.00 million during the quarter, compared to the consensus estimate of $600.83 million. During the same period last year, the company earned $0.85 EPS. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Royalty Pharma Price Performance

NASDAQ RPRX opened at $27.20 on Tuesday. Royalty Pharma has a one year low of $25.20 and a one year high of $31.66. The stock has a 50-day moving average of $27.95 and a 200 day moving average of $27.56. The company has a market capitalization of $16.14 billion, a price-to-earnings ratio of 24.07, a PEG ratio of 3.99 and a beta of 0.47. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $0.21 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 annualized dividend and a yield of 3.09%. Royalty Pharma’s payout ratio is 74.34%.

Analyst Ratings Changes

Several research firms recently commented on RPRX. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday. Morgan Stanley raised their target price on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. Citigroup dropped their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, The Goldman Sachs Group raised their target price on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Royalty Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.67.

Get Our Latest Analysis on RPRX

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

See Also